External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy.

Abstract

Importance:

Despite the benefit of peptide receptor radionuclide therapy (PRRT) for patients with well-differentiated neuroendocrine tumors (WD NETs), no clinical metric to anticipate benefit from the therapy for individual patients has been previously defined.

Objective:

To assess whether the prognostic ability of the clinical score (CS) could be validated in an external cohort of patients with WD NETs.

Design, Setting, and Participants:

This multicenter cohort study's analysis included patients with WD NETs who were under consideration for peptide receptor radionuclide therapy (PRRT) with lutetium-177 (177Lu)-dotatate between March 1, 2016, and March 17, 2020. The original cohort included patients from Vanderbilt-Ingram Cancer Center. The validation cohort included patients from Ochsner Medical Center, Markey Cancer Center, and Rush Medical Center. Patients with paragangliomas, pheochromocytomas and neuroblastomas were excluded. Statistical analysis was performed from June to November 2021.

Exposures:

PRRT with 177Lu-dotatate or alternate therapies such as everolimus, sunitinib, or capecitabine plus temozolomide.

Main Outcomes and Measures:

The primary outcome was progression-free survival (PFS) and was estimated by the Kaplan-Meier method; a Cox proportional-hazards model adjusting for primary tumor site, tumor grade, and number of PRRT doses administered was used to analyze association between CS and outcomes.

Results:

A total of 126 patients (median age [IQR] age: 63.6 [52.9-70.7] years; 64 male individuals) were included in the validation cohort, and the combined cohort (validation and original cohorts combined) had a total of 248 patients (median [IQR] patient age: 63.3 [53.3-70.3] years; 126 male individuals). In the validation cohort, on multivariable analysis, for each 2-point increase in CS, PFS decreased significantly (hazard ratio, 2.61; 95% CI, 1.64-4.16). After finding an association of the CS with PFS in the validation cohort, the original and validation cohorts were combined into the cohort for this analysis. On multivariable analysis, for each 2-point increase in CS, PFS decreased significantly (hazard ratio, 2.52; 95% CI, 1.89-3.36).

Conclusions and Relevance:

Increases in CS were associated with worsening PFS in the validation cohort, validating findings from the original cohort. These findings suggest that the CS, to our knowledge, represents the first clinical metric to estimate anticipated benefit from PRRT for patients with WD NETs and may be a clinical tool for patients being considered for PRRT.

• Authors: Satya Das, Aman Chauhan, Liping Du, Katharine E Thomas, Aasems Jacob, Aimee Schad, Shikha Jain, Aaron Jessop, Chirayu Shah, David Eisner, Dana B Cardin, Kristen K Ciombor, Laura W Goff, Marques Bradshaw, Dominique Delbeke, Martin Sandler, Robert A Ramirez, Jordan Berlin
• Journal: JAMA network open (JAMA Netw Open) Vol. 5 Issue 1 Pg. e2144170 (01 04 2022) ISSN: 2574-3805 [Electronic] United States
• PMID: 35044469 (Publication Type: Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Validation Study)

Chemical References

• Organometallic Compounds
• Radioisotopes
• Receptors, Peptide
• lutetium Lu 177 dotatate
• Octreotide

Topics

• Aged
• Cohort Studies
• Female
• Humans
• Kaplan-Meier Estimate
• Male
• Middle Aged
• Neuroendocrine Tumors (mortality, radiotherapy)
• Octreotide (analogs & derivatives, therapeutic use)
• Organometallic Compounds (therapeutic use)
• Predictive Value of Tests
• Prognosis
• Progression-Free Survival
• Proportional Hazards Models
• Prospective Studies
• Radioisotopes (therapeutic use)
• Radionuclide Imaging
• Receptors, Peptide (therapeutic use)
• Severity of Illness Index
• Treatment Outcome